ATYR PHARMA INC (LIFE)

US0021202025 - Common Stock

1.9  +0.05 (+2.7%)

After market: 1.94 +0.04 (+2.11%)

Fundamental Rating

2

Overall LIFE gets a fundamental rating of 2 out of 10. We evaluated LIFE against 570 industry peers in the Biotechnology industry. LIFE may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, LIFE is valued expensive at the moment.



1

1. Profitability

1.1 Basic Checks

In the past year LIFE has reported negative net income.
In the past year LIFE has reported a negative cash flow from operations.
LIFE had negative earnings in each of the past 5 years.
In the past 5 years LIFE always reported negative operating cash flow.

1.2 Ratios

LIFE has a Return On Assets (-47.62%) which is in line with its industry peers.
LIFE has a Return On Equity of -63.85%. This is comparable to the rest of the industry: LIFE outperforms 58.06% of its industry peers.
Industry RankSector Rank
ROA -47.62%
ROE -63.85%
ROIC N/A
ROA(3y)-39.44%
ROA(5y)-45.09%
ROE(3y)-49.97%
ROE(5y)-62.48%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

LIFE does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

3

2. Health

2.1 Basic Checks

LIFE does not have a ROIC to compare to the WACC, probably because it is not profitable.
LIFE has more shares outstanding than it did 1 year ago.
LIFE has more shares outstanding than it did 5 years ago.
The debt/assets ratio for LIFE is higher compared to a year ago.

2.2 Solvency

Based on the Altman-Z score of -4.12, we must say that LIFE is in the distress zone and has some risk of bankruptcy.
LIFE has a Altman-Z score of -4.12. This is in the lower half of the industry: LIFE underperforms 61.18% of its industry peers.
LIFE has a Debt/Equity ratio of 0.02. This is a healthy value indicating a solid balance between debt and equity.
LIFE has a Debt to Equity ratio of 0.02. This is comparable to the rest of the industry: LIFE outperforms 44.54% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Altman-Z -4.12
ROIC/WACCN/A
WACC8.87%

2.3 Liquidity

A Current Ratio of 6.07 indicates that LIFE has no problem at all paying its short term obligations.
LIFE has a Current ratio of 6.07. This is in the better half of the industry: LIFE outperforms 60.66% of its industry peers.
A Quick Ratio of 6.07 indicates that LIFE has no problem at all paying its short term obligations.
With a decent Quick ratio value of 6.07, LIFE is doing good in the industry, outperforming 61.01% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 6.07
Quick Ratio 6.07

4

3. Growth

3.1 Past

LIFE shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 37.93%, which is quite impressive.
LIFE shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -94.34%.
The Revenue for LIFE have been decreasing by -67.68% on average. This is quite bad
EPS 1Y (TTM)37.93%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%20.69%
Revenue 1Y (TTM)-94.34%
Revenue growth 3Y-67.68%
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 35.04% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 291.57% on average over the next years. This is a very strong growth
EPS Next Y2.52%
EPS Next 2Y9.08%
EPS Next 3Y26.27%
EPS Next 5Y35.04%
Revenue Next Year-19.38%
Revenue Next 2Y375.78%
Revenue Next 3Y505.83%
Revenue Next 5Y291.57%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for LIFE. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for LIFE. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as LIFE's earnings are expected to grow with 26.27% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y9.08%
EPS Next 3Y26.27%

0

5. Dividend

5.1 Amount

LIFE does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

ATYR PHARMA INC

NASDAQ:LIFE (6/4/2024, 8:12:25 PM)

After market: 1.94 +0.04 (+2.11%)

1.9

+0.05 (+2.7%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap129.87M
Analysts
Price Target
Short Float %
Short Ratio
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -47.62%
ROE -63.85%
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM N/A
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 6.07
Quick Ratio 6.07
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)37.93%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y2.52%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-94.34%
Revenue growth 3Y-67.68%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y